Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948214 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
A Phase 3 study of Growth Hormone Deficiency (GHD), sponsored by Lumos Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 17
- Study locations
NCT06948214: Recruiting Phase 3 study of Growth Hormone Deficiency (GHD), sponsored by Lumos Pharma.
NCT06948214 is a Phase 3 study of Growth Hormone Deficiency (GHD) that is actively recruiting participants, run by Lumos Pharma. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). The trial reports 17 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06948214, a Phase 3 study of Growth Hormone Deficiency (GHD), is actively recruiting participants, sponsored by Lumos Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 17
- Study locations
Study Summary
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
Primary Outcome
Annualized height velocity (AHV) measured as standing height with stadiometer
Conditions Studied
Interventions
- DRUG LUM-201
- OTHER Matched Placebo (Capsules)
Study Locations (17)
Colorado
- Lumos Pharma Investigational Site - Centennial
- Lumos Pharma Investigational Site - Greenwood Village
Florida
- Lumos Pharma Investigational Site - Orlando
- Lumos Pharma Investigational Site - Tallahassee
Alabama
- Lumos Pharma Investigational Site - Birmingham
California
- Lumos Pharma Investigational Site - Sacramento
District of Columbia
- Lumos Pharma Investigational Site - Washington D.C.
Louisiana
- Lumos Pharma Investigational Site - New Orleans
Minnesota
- Lumos Pharma Investigational Site - Minneapolis
Missouri
- Lumos Pharma Investigational Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
What NCT06948214 shows while recruiting
NCT06948214 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Growth Hormone Deficiency (GHD) appearing as the primary indexed condition, and to 2 interventions - of which LUM-201 is the first listed.
NCT06948214 lists 17 locations in 15 states (Colorado, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT06948214 about?
NCT06948214 is a clinical study titled "Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency". The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to re...
What is the current status of trial NCT06948214?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-04. Estimated completion is 2028-01.
What conditions does trial NCT06948214 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency (GHD).
What interventions are being tested in trial NCT06948214?
The interventions under investigation include: LUM-201 (DRUG), Matched Placebo (Capsules) (OTHER).
Who is sponsoring clinical trial NCT06948214?
This trial is sponsored by Lumos Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06948214 being conducted?
This trial has 17 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency (GHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06948214's enrollment target sits among peer trials
150 1520th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia